Ineffectiveness of Trioxsalen as an Oral Photosensitizer
Albert M. Kligman, MD, PhD;
Francis P. Goldstein
Arch Dermatol. 1973;107(3):413-414.
Abstract
The phototoxicity of methoxsalen (8-methoxypsoralen [8-MOP]) and trioxsalen (trimethylpsoralen) has been compared in humans.
Topically, both drugs evoked equivalently intense reactions at low concentrations after exposure to long ultra-violet rays from the filtered xenon lamp.
Whereas 60 mg of orally administered methoxsalen produced sharp reactions with occasional blistering, 200 mg of trioxsalen had no effect with long ultraviolet rays. Mild phototoxic responses were occasionally obtained with one-hour sunlight exposures after administration of 200 mg, but not less, of trioxsalen.
Since the dose of trioxsalen is usually not more than 20 mg, the claims of therapeutic value in vitiligo probably reflect observer error.
Author Affiliations
Philadelphia
From the Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia.
Footnotes
Accepted for publication Dec 7, 1972.
Reprint requests to Department of Dermatology, Hospital of the University of Pennsylvania, Duhring Laboratories, 3400 Spruce St, Philadelphia 19104 (Dr. Kligman).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Albert Kligman--Master of Dermatology
Leyden
Arch Dermatol 1991;127:1392-1393.
ABSTRACT
Photochemotherapy of Vitiligo: Use of Orally Administered Psoralens and a High-Intensity Long-Wave Ultraviolet Light System
Parrish et al.
Arch Dermatol 1976;112:1531-1534.
ABSTRACT
Topical Photosensitizers: Influence of Vehicles on Penetration
Kaidbey and Kligman
Arch Dermatol 1974;110:868-870.
ABSTRACT
Effectiveness of Trioxsalen Therapy for Vitiligo
Sehgal
Arch Dermatol 1974;110:957-958.
ABSTRACT
Photopigmentation With Trioxsalen
Kaidbey and Kligman
Arch Dermatol 1974;109:674-677.
ABSTRACT
Trioxsalen Therapy for Vitiligo
Sehgal
Arch Dermatol 1974;109:578-578.
ABSTRACT
|
